Article Figures & Data
Figures
- Figure 1
Summary of opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer. AE, adverse event; dMMR, mismatch-repair deficiency; MSI-H, high microsatellite instability; CRC, Colorectal cancer.
Tables
- Table 1
Efficacy of immune checkpoint inhibitor treatment of MSI-H/dMMR colorectal cancer in select clinical trials
Trial KEYNOTE 1645 KEYNOTE 0166 CheckMate 1427,8 Li et al.9 Li et al.10 Astrum01011 Prior treatment line ≥ 1 ≥ 2 ≥ 2 ≥ 1 ≥ 2 1 ≥ 2 ≥ 2 Treatment Pembrolizumab Pembrolizumab Nivolumab Nivolumab +Ipilimumab Tislelizumab Envafolimab Envafolimab Serplulimab Sample size (n) 63 61 40 74 119 46 24 41 53 Follow-up time 24 31 / 21 51 15 12 / cCR (%) 8 3 13 3 13 4 13 0 / ORR (%) 33 33 52 34 65 39 63 32 38 DCR (%) 57 51 82 62 96 72 67 59 / DoR (month) 4.4 to 23.6+ 6.2 to 31.3+ / 1.4 to 31.6 1.4+ to 50.8+ NR 2.8+ to 15.0+ 1.0+ to 16.6+ 1.6 to 13.1 PFS (month) 4.1 2.3 NR 6.6 NR NR NR 4.9 / 1Y-PFS (%) 41 34 / 44 71 / 63 32 / 2Y-PFS (%) 37 31 59 NR 60 / / / / 1Y-OS (%) 76 72 / 72 85 / 87 65 / 2Y-OS (%) 63 55 72 / 74 / / / / cCR, clinical complete response; DCR, disease control rate; DoR, duration of response; NR, not reported; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; Y, year.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.